(19)
(11) EP 4 815 952 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24827581.0

(22) Date of filing: 29.11.2024
(51) International Patent Classification (IPC): 
A61K 31/506(2006.01)
A61P 35/04(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61P 35/04; A61K 31/506
(86) International application number:
PCT/US2024/057943
(87) International publication number:
WO 2025/117875 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 29.11.2023 US 202363604042 P
15.12.2023 US 202363610444 P

(71) Applicant: Tyra Biosciences, Inc.
Carlsbad, CA 92008 (US)

(72) Inventors:
  • TADA, Hiroomi
    Carlsbad, California 92008 (US)
  • BURN, Timothy, Campbell
    Carlsbad, California 92008 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) COMPOUNDS FOR TREATING SOLID TUMORS HAVING ACTIVATING FGFR2 GENE ALTERATIONS